Mater Med Pol. 1996 Jul-Sep;28(3):83-6.

An analgesic effect of synthetic human calcitonin in patients with primary osteoporosis.

Materia medica Polona. Polish journal of medicine and pharmacy

P Kapuściński, M Tałałaj, J Borowicz, E Marcinowska-Suchowierska, R Brzozowski

PMID: 9167417

Abstract

Examinations were performed in 20 adult male and female patients (pts) suffering from acute back pain due to vertebral compression fracture secondary to osteoporosis proved by lateral X-rays of the dorso-lumbar spine (Th3-L5), and bone mineral density with the method of dual energy X-ray absorptiometry. The synthetic human calcitonin (SUC) (0.5 mg) was injected I.M. every day during 28 days. Analgesic effect was evaluated on 0, 3, 7, 14, 21 and 28th day by patient's assessment of functional capacity, and physician's assessment of pain and mobility. On the same days biochemical variables of Ca-P homeostasis were determined. Treatment with calcitonin resulted in a positive analgesic effect. The functional capacity and mobility of pts increased with diminution of pain. No significant alterations of Ca-P homeostasis was observed. Mild and transient side effects as nausea and tachycardia were negligible. SHC appears to have a significant analgesic effect in treatment of primary osteoporosis.

Substances

• Analgesics
• Calcitonin

MeSH terms

• Adult
• Aged
• Analgesics / therapeutic use
• Calcitonin / therapeutic use
• Female
• Humans
• Male
• Middle Aged
• Osteoporosis / complications
• Pain / drug therapy
• Pain / etiology

Publication Types

• Journal Article
• Research Support, Non-U.S. Gov't